GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Delcath Systems Inc (STU:DV3R) » Definitions » Short Interest

Delcath Systems (STU:DV3R) Short Interest


View and export this data going back to 2012. Start your Free Trial

What is Delcath Systems Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data is no longer available on GuruFocus website.

Competitive Comparison of Delcath Systems's Short Interest

For the Medical Devices subindustry, Delcath Systems's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Delcath Systems's Short Interest Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Delcath Systems's Short Interest distribution charts can be found below:

* The bar in red indicates where Delcath Systems's Short Interest falls into.


;
;

Delcath Systems Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Delcath Systems Inc (STU:DV3R) » Definitions » Short Interest
Comparable Companies
SRDX SENS LAB VREX NPCE TANAF BBNX CTKB SMLR TMCI ABT BSX SYK MDT XTER:SHL EW SZSE:300760 DXCM XAMS:PHIA ZBH
Traded in Other Exchanges
DCTH:USA DV3R:Germany
Address
566 Queensbury Avenue, Queensbury, NY, USA, 12804
Website
https://www.delcath.com
Delcath Systems Inc is an oncology company. It is focused on the treatment of primary and metastatic liver cancers. The firm's product, Melphalan Hydrochloride for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. The company operates in one reportable segment which includes the research, development, manufacture, and distribution of hepatic delivery systems for use in the treatment of specific conditions. The Company operates its business in the United States and Europe.

Delcath Systems Headlines

No Headlines